查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470588

皮膚癌診斷與治療藥物市場：依疾病類型和類型分類－2024-2030年全球預測

Skin Cancer Diagnostics & Therapeutics Market by Disease Type (Melanoma, Non-melanoma), Type (Diagnosis, Therapeutics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年皮膚癌診斷與治療藥物市場規模為75.4億美元，2024年達83.1億美元，2030年達151.1億美元，預計複合年成長率為10.43%。

皮膚癌診斷包括早期發現皮膚癌的各種程序和技術。診斷過程通常從皮膚檢查開始，以識別可疑病變或痣。被診斷出患有皮膚癌後，我們進入治療階段。治療方法取決於癌症的類型和階段，可能包括切除、莫氏手術或冷凍手術等外科手術。還有非手術治療方法，如放射線治療、化療、免疫治療、動態治療等，可單獨使用或與手術治療合併使用。全球皮膚癌發病率上升、醫療保健投資和基礎設施增加以及政府和非營利組織提高意識提升計劃正在推動對皮膚癌診斷和治療的需求。將個人化醫療和基因組學引入治療方案也是一個強大的推動力。然而，與先進診斷和治療相關的高成本、與治療相關的潛在副作用和併發症以及獲得醫療保健服務的差異可能會阻礙成長。此外，與皮膚癌診斷和治療相關的程序和技術困難以及熟練人力資源的缺乏也是主要挑戰。然而，主要參與者正在探索新的創新領域，包括改進精準醫療技術、開發毒性較小、更有效的藥物配方，以及探索免疫療法和生技藥品等新興領域的潛力，我們的目標是簡化和簡化護膚診斷和治療。

主要市場統計
基準年[2023] 75.4億美元
預測年份 [2024] 83.1億美元
預測年份 [2030] 151.1億美元
複合年成長率（%） 10.43%

疾病類型 對黑色素瘤快速、早期診斷和治療的需求不斷增加

黑色素瘤是一種嚴重的皮膚癌，發生在產生黑色素的細胞中，黑色素是賦予皮膚顏色的色素。診斷需要皮膚鏡檢查、皮膚切片檢查、淋巴結定位和影像檢查等方法，治療包括手術切除、化療、標靶治療和免疫治療。這些選項的優先順序取決於腫瘤特徵、分期和患者健康狀況。與非黑色素瘤皮膚癌相比，黑色素瘤轉移的機會更高，因此需要更積極的治療和持續監測。隨著疾病的進展，預後通常會惡化。因此，強調早期、準確的診斷。非黑色素瘤皮膚癌主要包括基底細胞癌（BCC）和鱗狀細胞癌（SCC），它們的侵襲性通常低於黑色素瘤。雖然這些癌症更常見，但轉移的風險要低得多，治療通常包括手術切除、冷凍手術和早期局部藥物治療。也可以使用動態療法或放射線治療。非黑色素瘤的治療和診斷通常比黑色素瘤的治療便宜且複雜。

隨著皮膚癌患者數量的增加，皮膚癌的治療方法正在不斷改善。

診斷在皮膚癌的治療中起著至關重要的作用，可以實現早期發現並增加成功治療的可能性。診斷領域包括各種技術和方法，例如皮膚鏡檢查、切片檢查、影像檢查和分子診斷。儘管血液檢查不常用於診斷皮膚癌，但它們可以提供有關患者整體健康狀況和器官功能的寶貴資訊，特別是在癌症可能已經擴散的晚期病例中。皮膚鏡檢查是一種用於檢查皮膚病變的非侵入性診斷工具。超音波、X 光、電腦斷層掃描 (CT)、正子斷層掃描 (PET) 和磁振造影(MRI) 等影像檢查可以幫助檢測皮膚癌是否擴散到身體其他部位。如果懷疑皮膚癌已經擴散，可以進行淋巴結切片檢查以評估癌細胞是否已擴散到淋巴系統。皮膚切片檢查是診斷皮膚癌的主要方法。取出可疑的皮膚組織並在顯微鏡下檢查以檢查是否有癌細胞。皮膚癌的治療方法包括手術到先進的全身療法和免疫療法，治療方法的選擇通常取決於皮膚癌的階段和類型。化療是針對各階段的皮膚癌的有效全身性治療方法，尤其是轉移性或進行性。這種治療方法使用口服或靜脈注射的抗癌藥物來破壞快速分裂的癌細胞。非侵入性治療方法越來越受到關注，因為它們透過靶向癌細胞而對周圍健康組織的損害最小，從而提供顯著的益處。這些治療方法包括局部治療、放射線治療和動態治療。外科手術的範圍從果凍技術（例如冷凍並破壞異常組織）到更廣泛的手術（例如莫氏手術），逐層去除癌組織，同時保留盡可能多的健康組織。

區域洞察

美洲，特別是美國和加拿大，擁有先進的醫療保健系統，在皮膚癌研究和診斷方面投入大量資金。患者行為是由高度認知和獲得先進治療的機會所驅動的。公共和私人組織正在提供財務支持和舉措，以降低皮膚癌的發病率和死亡率。該領域的專利數量很高，代表了診斷工具（如痣繪圖技術、人工智慧影像分析）以及治療方法（如標靶治療和免疫療法）的重要創新。在歐盟（EU），成員國之間皮膚癌的盛行率和醫療保健的取得情況存在很大差異。儘管對皮膚癌研究和醫療基礎設施的投資各不相同，但人們正在透過歐盟的地平線 2020 計畫等舉措共同努力協調和推進對抗皮膚癌的鬥爭。在亞太地區，政府對改善醫療基礎設施的支持力道不斷加大，保險普及不斷提高，導致皮膚癌治療的需求不斷增加。日本和澳洲等擁有先進醫療保健系統的國家在患者支出和創新治療方法的採用方面處於領先地位。

FPNV定位矩陣

FPNV 定位矩陣對於評估皮膚癌診斷和治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對皮膚癌診斷和治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.皮膚癌診斷及治療藥物市場規模及預測如何？

2.皮膚癌診斷和治療市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.皮膚癌診斷和治療藥物市場的技術趨勢和法規結構是什麼？

4.皮膚癌診斷及治療藥物市場主要廠商的市場佔有率是多少？

5.進入皮膚癌診斷/治療藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球皮膚癌發生率和認知不斷提高
      • 加強政府對皮膚癌的早期發現和治療的努力
      • 皮膚癌診斷和治療的開發平臺快速成長
    • 抑制因素
      • 各種皮膚癌治療的高成本
    • 機會
      • 皮膚癌診斷與治療藥物研究進展
      • 新興國家皮膚癌治療的發展
    • 任務
      • 皮膚癌放射治療的副作用
  • 市場區隔分析
    • 疾病類型：對惡性黑色素瘤的快速、早期診斷和治療的需求日益成長
    • 類型：改善皮膚癌治療方法的進展以滿足不斷成長的皮膚癌患者數量
  • 市場趨勢分析
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章皮膚癌診斷與治療藥物市場：依疾病類型

  • 惡性黑色素瘤
  • 非黑色素瘤

第7章皮膚癌診斷與治療藥物市場：依類型

  • 診斷
  • 治療藥物

第8章北美和南美皮膚癌診斷和治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區皮膚癌診斷與治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲皮膚癌診斷和治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准首個人工智慧驅動的皮膚癌診斷工具
    • Sun Pharma 與 Philogen 合作在歐洲實現皮膚癌治療的商業化
    • Insight 宣布 FDA核准Zynyz (Retifanlimab-Dlwr) 用於治療轉移性/復發性局部進行性默克爾細胞癌 (MCC)

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4342CA3266E1

[192 Pages Report] The Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 7.54 billion in 2023 and expected to reach USD 8.31 billion in 2024, at a CAGR 10.43% to reach USD 15.11 billion by 2030.

Skin cancer diagnostics involve a range of procedures and technologies designed to detect skin cancer at its earliest stages. The diagnostic process typically starts with a physical examination of the skin to identify suspicious lesions or moles. Once skin cancer is diagnosed, the therapeutic stage involves the treatment of the disease. Treatments can vary, as it depends on the type and stage of the cancer, and may include surgical procedures, including excision, Mohs surgery, and cryosurgery. Non-surgical options such as radiation therapy, chemotherapy, immunotherapy, and photodynamic therapy are also available and may be used either alone or in combination with surgical treatments. The rising incidence of skin cancer globally, increased healthcare investment and infrastructure, and growing awareness programs by governments and non-profit organizations have accentuated the need for skin cancer diagnostics and therapeutics. The introduction of personalized medicine and genomics into treatment protocols is also a potent driver. However, the high costs associated with advanced diagnostics and therapy, potential side effects and complications related to treatment, and disparities in access to healthcare services can impede the growth. Additionally, the procedural and technical difficulties associated with the diagnosis and therapy for skin cancer, coupled with a lack of skilled personnel, pose significant challenges. However, key players are exploring new areas of innovation, including the refinement of precision medicine techniques, the development of less toxic and more effective drug formulations, and exploring the potential of emerging fields such as immunotherapy and biologics to improve the efficiency and ease of skin care diagnostics and therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 7.54 billion
Estimated Year [2024] USD 8.31 billion
Forecast Year [2030] USD 15.11 billion
CAGR (%) 10.43%

Disease Type: Growing need to ensure quick and early diagnosis and treatment of melanomas

Melanoma is a severe form of skin cancer originating in the cells that produce melanin, the pigment that gives skin its color. For diagnostics, methods such as dermoscopy, skin biopsies, lymph node mapping, and imaging tests are in demand, while treatments range from surgical excision and chemotherapy to targeted therapy and immunotherapy. Preference for these options varies based on the tumor's characteristics, staging, and patient health. Compared to non-melanoma skin cancers, melanoma requires more aggressive treatment and ongoing surveillance due to its high metastatic potential. The prognosis generally worsens with later-stage diagnoses. Therefore, early and accurate diagnostics are heavily emphasized. Non-melanoma skin cancers predominantly include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), which are generally less aggressive than melanoma. Although these cancers are more common, they have a significantly lower risk of spreading, and the treatment often involves local procedures such as surgical excision, cryosurgery, or topical medications for early stages. Photodynamic therapy and radiation may also be utilized. Non-melanoma treatments and diagnostics are usually less expensive and less complex than those for melanoma.

Type: Advancements to improve therapeutics for skin cancer to cater to the rising incidences of skin cancer patients

Diagnosis plays a highly critical role in the management of skin cancer, enabling early detection and thereby increasing the likelihood of successful treatment outcomes. The diagnostic segment includes various technologies and methods such as dermatoscopy, biopsy, imaging tests, and molecular diagnostics. While blood tests are not commonly used to diagnose skin cancer, they can provide valuable information about the patient's overall health and organ function, particularly in advanced cases where cancer may have spread. Dermatoscopy refers to a non-invasive diagnostic tool used to examine skin lesions. Imaging tests such as ultrasound, X-rays, computed tomography (CT) scans, positron emission tomography (PET), or magnetic resonance imaging (MRI) scans may be used to determine the spread of skin cancer to other parts of the body. When there is a suspicion of skin cancer spread, a lymph node biopsy can be performed to evaluate whether cancer cells have metastasized to the lymphatic system. A skin biopsy is the primary method used to diagnose skin cancer. It involves removing a sample of suspicious skin tissue, which is then examined under a microscope for the presence of cancer cells. The therapeutics for skin cancer range from surgical treatments to advanced systemic therapies and immunotherapies, with the choice of treatment usually dependent on the stage and type of skin cancer. Chemotherapy remains a potent systemic treatment modality for various stages of skin cancer, particularly for metastatic or advanced disease. It involves the use of anti-cancer drugs that are administered orally or intravenously to destroy rapidly dividing cancer cells. Non-invasive therapies have gained traction as they offer significant advantages by targeting cancer cells while minimizing damage to surrounding healthy tissue. These therapies include topical treatments, radiotherapy, or photodynamic therapy. Surgical procedures range from minimally invasive techniques such as cryosurgery, which involves freezing and destroying abnormal tissue, to more extensive surgeries such as Mohs surgery, which removes cancerous tissue layer by layer while preserving as much healthy tissue as possible.

Regional Insights

The Americas region, particularly the U.S. and Canada, harbors a sophisticated healthcare system with substantial investments in skin cancer research and diagnostics. Patient behavior is driven by high awareness levels and access to advanced therapies. Public and private entities show commitment through funding and initiatives to reduce the incidence and death rates associated with skin cancer. There is a high number of patents in the field, showcasing significant innovation in diagnostic tools such as mole mapping technologies, AI-driven image analysis, and therapeutic approaches, including targeted therapies and immunotherapies. The European Union shows substantial heterogeneity in the prevalence of skin cancer and healthcare access across member states. Investments in skin cancer research and healthcare infrastructures vary, but there is a concerted effort, showcased through initiatives such as the EU's Horizon 2020 program, to harmonize and advance the fight against skin cancer. In the APAC region, rising government support for improving the healthcare infrastructure and increasing insurance penetration is translating into a greater need for skin cancer care. Countries with advanced healthcare systems, such as Japan and Australia, lead in patient expenditure and adoption of innovative therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Skin Cancer Diagnostics & Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Skin Cancer Diagnostics & Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Skin Cancer Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AB Science, Abbott Laboratories, Agilent Technologies, Inc., Almirall, S.A., Amgen, Inc., AMLo Biosciences Ltd., AstraZeneca PLC, bioMerieux SA, Bristol-Myers Squibb Company, Castle Biosciences, Inc., Daiichi Sankyo Company, Limited, DAMAE Medical, DermTech, Inc. by Bausch Health Companies Inc., Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., NeraCare GmbH, Novartis AG, Pfizer Inc., QIAGEN N.V., Sanofi S.A., Sirnaomics, Inc., SkylineDx BV, Sun Pharmaceutical Industries Ltd., and Veriskin Inc..

Market Segmentation & Coverage

This research report categorizes the Skin Cancer Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Melanoma
    • Non-melanoma
  • Type
    • Diagnosis
      • Blood Tests
      • Dermatoscopy
      • Imaging Tests
      • Lymph Node Biopsy
      • Skin Biopsy
    • Therapeutics
      • Chemotherapy
      • Non-invasive Therapy
      • Surgery
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Skin Cancer Diagnostics & Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Skin Cancer Diagnostics & Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Skin Cancer Diagnostics & Therapeutics Market?

4. What is the market share of the leading vendors in the Skin Cancer Diagnostics & Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Skin Cancer Diagnostics & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Incidences and Rising Awareness of Skin Cancer Globally
      • 5.1.1.2. Rising Government Initiatives for Early Detection and Skin Cancer Treatment
      • 5.1.1.3. Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost Associated With the Various Skin Cancer Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Skin Cancer Diagnostics & Therapeutics
      • 5.1.3.2. Developments of Skin Cancer Care in Emerging Nations
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects of Radiation Therapy for Skin Cancer
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing need to ensure quick and early diagnosis and treatment of melanomas
    • 5.2.2. Type: Advancements to improve therapeutics for skin cancer to cater to the rising incidences of skin cancer patients
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Melanoma
  • 6.3. Non-melanoma

7. Skin Cancer Diagnostics & Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Therapeutics

8. Americas Skin Cancer Diagnostics & Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
    • 11.3.2. Sun Pharma, Philogen Collaborate to Commercialise Skin Cancer Drug in Europe
    • 11.3.3. Incyte Announces FDA Approval Of Zynyz (Retifanlimab-Dlwr) For Treatment Of Metastatic/Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. QATA